Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract at European Society for Medical Oncology (ESMO) Congress 2021

NEXT STORY
Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy
PREV STORY
Global Blood Gas and Electrolyte Analyzers Market to Reach $985 Million by 2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology

author_avatar
NASDAQ Market News

Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)

– Single Agent Ivosidenib Demonstrated CR+CRh Rate of 42.4% and Overall Response Rate (ORR) ...

author_avatar
NASDAQ Market News

bioAffinity Technologies Selected as Finalist for Cancer Innovation Award

author_avatar
NASDAQ Market News